Reverse transcriptase is an enzyme that synthesizes DNA using RNA as a template. This process, called reverse transcription, transfers genetic sequence information in the opposite direction to conventional transcription, in which RNA is copied from DNA. Reverse transcriptases are diverse proteins, not a single universally identical enzyme. Many also copy DNA templates, and some combine DNA synthesis with an activity that degrades RNA in RNA–DNA hybrids.
Reverse transcriptase is essential to the replication of retroviruses, including human immunodeficiency virus (HIV), but its biological distribution extends well beyond these viruses. Related enzymes mobilize genetic elements, maintain chromosome ends, and participate in bacterial defense systems. Their activities have helped shape the organization and evolution of genomes.
The discovery of reverse transcriptase in 1970 transformed understanding of genetic information flow. Its subsequent development as a laboratory reagent made it possible to convert RNA into stable, amplifiable complementary DNA (cDNA). Reverse transcriptases now underpin RNA analysis, many molecular diagnostic assays, transcriptome sequencing, and several forms of genome engineering.
Discovery and the interpretation of genetic information flow
During the 1950s and 1960s, the relationship between RNA tumor viruses and heritable changes in infected cells presented a major problem in molecular biology. These viruses carried RNA, yet infection could establish a persistent state that was transmitted when cells divided. Howard Temin, studying Rous sarcoma virus, proposed that an infected cell contained a DNA copy of the viral genetic information. His “provirus hypothesis” offered a mechanism for persistence: viral information could become part of cellular DNA rather than remain solely as unstable RNA.
In 1970, two independent research groups reported the crucial enzymatic evidence. Howard Temin and Satoshi Mizutani, working with Rous sarcoma virus, and David Baltimore, working with murine leukemia virus, demonstrated RNA-dependent DNA synthesis associated with virus particles. Their papers appeared together in Nature. The experiments showed that retroviral particles contained an enzyme capable of producing DNA, providing a biochemical mechanism for Temin’s proposed DNA intermediate. In 1975, Temin, Baltimore, and Renato Dulbecco shared the Nobel Prize in Physiology or Medicine for discoveries concerning the interaction between tumor viruses and cellular genetic material.
The discovery is often described as overturning the central dogma of molecular biology, but that description requires qualification. Francis Crick’s formulation concerned possible transfers of sequence information among nucleic acids and proteins, particularly the exclusion of transfer from protein sequence back into nucleic acid sequence. Reverse transcription contradicted a simplified textbook picture in which information always moves from DNA to RNA to protein; it did not demonstrate information transfer from protein back to DNA or RNA. Its importance lay in establishing a major biological pathway that the simplified picture omitted.
Subsequent discoveries expanded the enzyme’s significance. Reverse transcriptases were found in mobile genetic elements, hepatitis B virus replication, and chromosome-end maintenance. The identification of telomerase activity by Carol Greider and Elizabeth Blackburn in 1984, reported in 1985, revealed a cellular enzyme that uses an internal RNA template to extend DNA. Meanwhile, purification and recombinant production of viral reverse transcriptases made RNA copying a routine laboratory procedure. Structural studies, including HIV-1 reverse transcriptase structures reported in 1992, connected the enzyme’s catalytic mechanism to the design and interpretation of antiviral drugs. Reverse transcriptase thus developed from evidence for a controversial viral replication pathway into a broad class of enzymes central to virology, genome biology, and biotechnology.
Catalytic mechanism and molecular architecture
Reverse transcriptase belongs functionally to the DNA polymerases. It extends an existing nucleic-acid strand rather than ordinarily initiating DNA synthesis without a primer. A primer supplies a free -hydroxyl group, while the template determines which incoming deoxyribonucleotide is incorporated. The growing DNA strand is extended in the direction as the enzyme reads its template in the opposite direction. Depending on the enzyme and biological context, the primer may be RNA, DNA, or a hydroxyl group supplied by a protein.
The polymerization reaction can be represented schematically as
The primer’s terminal hydroxyl attacks the incoming nucleotide’s alpha phosphate, creating a phosphodiester bond and releasing pyrophosphate. Conserved acidic amino-acid residues coordinate divalent metal ions, usually magnesium under physiological conditions. These metals help position the substrates and facilitate the chemistry. Manganese can support synthesis by some reverse transcriptases in laboratory reactions, but changing the metal can alter substrate discrimination and error rates. Base pairing contributes specificity, while the enzyme’s active-site geometry provides additional selection among incoming nucleotides.
Many reverse transcriptase polymerase domains have an architecture described as a right hand, with fingers, palm, and thumb subdomains. The palm contains the catalytic residues; the fingers participate in nucleotide binding and positioning; and the thumb helps grip the template–primer duplex. HIV-1 reverse transcriptase is a particularly well-characterized example. Its mature form is an asymmetric heterodimer consisting of approximately 66-kilodalton and 51-kilodalton subunits, designated p66 and p51. The larger subunit supplies the polymerase and ribonuclease H active sites, while p51 primarily supports the functional architecture. Other reverse transcriptases are monomeric or have different oligomeric organizations, so the HIV arrangement is not universal.
Ribonuclease H, usually abbreviated RNase H, cleaves RNA when it is paired with DNA. In retroviral reverse transcription, this activity removes much of the RNA template as DNA synthesis proceeds. The polymerase and RNase H active sites are physically separated, enabling the same nucleic-acid substrate to engage both regions. Their coordination depends on substrate sequence, structure, and enzyme movement. Not all reverse transcriptases contain an RNase H domain: telomerase and many mobile-element enzymes do not. Consequently, “reverse transcriptase” identifies a core polymerization capability rather than a fixed combination of domains or a single replication mechanism.
Reverse transcription during retroviral replication
Retroviruses package two copies of their positive-sense RNA genome together with reverse transcriptase and other viral proteins. After entry into a susceptible cell, the viral RNA is converted into double-stranded DNA within a viral nucleoprotein environment. In HIV-1, reverse transcription is coordinated with changes in the capsid and with intracellular trafficking. It is therefore not simply a reaction performed by a freely dispersed enzyme in the cytoplasm. The resulting DNA becomes a substrate for viral integrase, which inserts it into host chromosomal DNA to form a provirus.
The reaction begins when a host transfer RNA anneals to a complementary primer-binding site near the viral RNA’s end. HIV-1 principally uses tRNA. Reverse transcriptase extends this primer toward the RNA’s terminus, producing minus-strand strong-stop DNA. RNase H degradation of the copied RNA exposes DNA sequences that can pair with a matching repeat at the RNA’s end. This first strand transfer allows minus-strand DNA synthesis to continue across most of the viral genome. The repeated terminal sequences are therefore functional components of a copying strategy, not merely redundant genetic material.
As minus-strand synthesis progresses, RNase H removes most of the original RNA. A relatively resistant RNA segment, the polypurine tract, supplies a primer for plus-strand DNA synthesis. HIV-1 also contains a central polypurine tract that contributes to its characteristic DNA synthesis intermediates. Removal of the tRNA primer and subsequent pairing of complementary primer-binding-site sequences permit a second strand transfer. Extension of both DNA strands produces a linear double-stranded molecule with long terminal repeats at both ends. These repeats contain regulatory and integration-related sequences assembled through the copying and transfer reactions.
Reverse transcription and integration are distinct processes. Reverse transcriptase makes DNA; integrase catalyzes its insertion into the host chromosome. Once integrated, proviral DNA can be copied during cellular DNA replication and transcribed by host RNA polymerase II. The resulting RNAs serve as viral genomes or as messenger RNAs for viral protein production. Reverse transcriptase is commonly produced within a larger viral polyprotein and matured by viral protease, helping coordinate enzyme availability with particle assembly.
Packaging two RNA genomes also permits copying to switch between templates. Such switching can rescue synthesis when a template is damaged and can generate recombinant viral genomes when the packaged RNAs differ. This capacity links the physical mechanism of reverse transcription directly to retroviral genetic variation.
Distribution in viruses, mobile elements, and bacteria
Reverse transcriptases occur in several biological systems that do not follow the retroviral life cycle. Hepatitis B virus is a prominent example. Its infectious particles contain a partly double-stranded DNA genome, but replication proceeds through an RNA intermediate called pregenomic RNA. The viral polymerase binds this RNA and initiates DNA synthesis through protein priming: a tyrosine residue in the polymerase’s terminal-protein domain supplies the initial attachment point. Reverse transcription occurs inside assembling nucleocapsids, and RNase H activity removes the RNA template. Thus, a virus classified by its DNA genome can nevertheless depend on reverse transcription.
In eukaryotic genomes, retrotransposons spread through RNA intermediates. Long-terminal-repeat retrotransposons share important mechanistic features with retroviruses, including reverse transcription and integration, but generally lack the machinery required for an extracellular infectious cycle. Non-LTR retrotransposons use a different strategy. Human LINE-1 elements encode an ORF2 protein with endonuclease and reverse transcriptase activities. The endonuclease nicks chromosomal DNA, and the exposed -hydroxyl can prime copying of the element’s RNA directly at the insertion site. This mechanism is called target-primed reverse transcription.
LINE-1 machinery can also mobilize RNAs that do not encode their own reverse transcriptase. Alu elements are a major example, while cellular messenger RNAs can occasionally generate processed pseudogenes. These relationships distinguish autonomous elements, which encode essential mobilization machinery, from nonautonomous elements that exploit another element’s proteins. Reverse transcription has consequently contributed to genome expansion, rearrangement, and the redistribution of gene-derived sequences. Most individual retrotransposon copies in the human genome are no longer capable of independent mobilization.
Group II introns provide another mechanistically distinctive setting. These mobile elements combine catalytic RNA with an intron-encoded protein that often contains reverse transcriptase activity. Following RNA splicing, an intron ribonucleoprotein can insert the intron RNA into a DNA target, after which reverse transcription helps establish a DNA copy. Their combination of RNA catalysis, mobility, and RNA processing has made them important to discussions of the origins of spliceosomal introns.
Bacterial reverse transcriptases include those associated with retrons and diversity-generating retroelements. Retrons produce unusual RNA-linked DNA molecules called multicopy single-stranded DNA; many characterized retron systems participate in defense against bacteriophages. Diversity-generating retroelements instead introduce variation into selected protein-coding regions, often affecting ligand-binding proteins. These examples show that reverse transcriptase can function in targeted diversification and defense rather than in wholesale copying of a viral genome.
Telomerase and chromosome-end maintenance
Telomerase is a specialized reverse transcriptase that extends telomeres, the nucleoprotein structures at the ends of linear eukaryotic chromosomes. Conventional DNA replication cannot fully reproduce chromosome termini by ordinary primer-dependent synthesis alone. Processing of chromosome ends adds further complexity to the maintenance problem. Without compensating mechanisms, repeated cell divisions can therefore lead to progressive telomere shortening. Telomerase counteracts this loss by adding short DNA repeats to the chromosome’s end.
The catalytic core contains telomerase reverse transcriptase, commonly abbreviated TERT, and a telomerase RNA that supplies the template. Unlike a retroviral enzyme copying a long external RNA genome, telomerase repeatedly uses a short template segment within its associated RNA. In humans, it synthesizes repeats of the sequence -TTAGGG-. After completing one repeat, the enzyme can reposition the DNA relative to the template and begin another cycle. This repeat-addition processivity depends on coordinated interactions among TERT, the RNA, and the DNA substrate.
Telomerase acts within a larger cellular system. Human telomerase RNA associates with proteins involved in RNA stability and ribonucleoprotein assembly, including dyskerin. At chromosome ends, the shelterin protein complex controls access and helps distinguish natural telomeres from broken DNA. The shelterin component TPP1 contributes to telomerase recruitment and processivity, while other factors help coordinate extension of the complementary DNA strand. Telomere maintenance therefore requires more than the catalytic addition of repeats: it also depends on chromosome-end protection, replication, and regulated enzyme recruitment.
Telomerase activity varies substantially among cell types. It is found in germ cells, many stem and progenitor populations, and activated lymphocytes, whereas many differentiated human somatic cells have little or no detectable activity. Telomerase is active in most human cancers, helping sustain proliferative capacity, but some tumors maintain telomeres through recombination-associated mechanisms collectively called alternative lengthening of telomeres. These observations connect telomerase to both normal tissue renewal and cancer biology without making it a universal explanation for either cellular aging or tumor formation.
Inherited defects affecting telomerase components or other telomere-maintenance proteins can cause telomere biology disorders. Their manifestations may include bone-marrow failure, pulmonary fibrosis, or liver disease, with considerable variation among affected individuals and families. Mechanistically, telomerase differs sharply from viral reverse transcriptase: it copies a built-in template, operates at a specialized chromosomal structure, and is regulated by host developmental and tissue-specific programs. Its discovery established that reverse transcription is not solely a viral or parasitic process but can be an integral part of normal chromosome biology.
Fidelity, template switching, and genetic evolution
Reverse transcriptases differ markedly in accuracy, but many viral examples are less faithful than replicative cellular DNA polymerases. A major reason is that they generally lack the exonuclease proofreading activity found in many high-fidelity DNA polymerases. Once a mismatched nucleotide has been incorporated, the enzyme may extend the mismatched primer rather than remove the error. Accuracy also depends on nucleotide concentrations, metal ions, template sequence, RNA structure, and the identity of the reverse transcriptase.
Reported error frequencies are consequently assay-dependent. For HIV-1 reverse transcriptase, biochemical measurements commonly fall within a broad range of approximately to errors per incorporated nucleotide, although individual estimates can lie outside that range. Such values should not be equated directly with the mutation rate of an intact virus in an infected organism. Whole-cycle measurements also incorporate errors made during RNA transcription, cellular editing, selection against defective genomes, and biases introduced by experimental detection. A purified enzyme’s fidelity is one component of viral mutagenesis, not a complete description of it.
Template switching creates another source of variation. A growing DNA strand can disengage from one RNA region and resume synthesis on a homologous region of the same or another template. In retroviruses, the presence of two packaged RNA genomes makes switching between molecules possible. If those genomes differ, the resulting DNA may combine their sequence variants. This form of recombination can bring mutations together or separate them, while also producing deletions and other rearrangements. Sequence similarity, RNA breaks, local secondary structure, and pausing of the polymerase all influence switching.
These mechanisms contribute to viral evolution, but variation and evolutionary success are not equivalent. Most random sequence changes are neutral or harmful in a particular environment, and many replication products are defective. Natural selection acts on the variants that remain capable of replication. Drug exposure, immune responses, and transmission bottlenecks alter which variants persist. In HIV, the combination of replication, mutation, and recombination helps explain why resistance can arise, but no single enzyme property determines the outcome.
Some reverse-transcription systems deliberately concentrate variation. Diversity-generating retroelements copy a template region into a related variable region while preferentially introducing substitutions at positions corresponding to adenines in the template RNA. This produces localized protein diversity without imposing equally high mutation rates across an entire genome. In laboratory applications, by contrast, unintended errors and template switches are generally undesirable because they can create apparent RNA variants, fusion transcripts, or sequence polymorphisms. The same chemical flexibility that supports biological diversification can therefore become a source of analytical artifacts.
Reverse transcriptase as an antiviral drug target
Reverse transcriptase is an important antiviral target because it performs an essential step in the replication of HIV and hepatitis B virus. Inhibition can prevent formation of the DNA intermediates needed for productive infection. Selectivity depends on differences between viral reverse transcriptases and host enzymes, although those differences are not absolute. Drug activity, cellular metabolism, viral sequence, and effects on host polymerases all contribute to the pharmacology of individual compounds.
Nucleoside and nucleotide reverse transcriptase inhibitors act as analogues of normal DNA precursors. After conversion to active phosphorylated forms inside cells, they compete with natural deoxyribonucleotides and can be incorporated into growing viral DNA. Many lack an appropriate -hydroxyl group, preventing ordinary extension after incorporation. Zidovudine, approved in the United States in 1987, was the first antiretroviral drug approved for HIV treatment. Other examples include lamivudine, emtricitabine, abacavir, and tenofovir-based drugs. Tenofovir is a nucleotide analogue, whereas several other members of the class are nucleoside analogues; their activation pathways therefore differ.
Non-nucleoside reverse transcriptase inhibitors act through a separate mechanism. Drugs such as nevirapine, efavirenz, and rilpivirine bind an allosteric pocket in HIV-1 reverse transcriptase rather than serving as substrates for DNA synthesis. Their binding alters conformational behavior and interferes with efficient polymerization. This pocket is not functionally equivalent across all reverse transcriptases, and the class does not provide a general means of inhibiting every virus that uses reverse transcription. HIV-2, for example, is intrinsically resistant to the clinically used HIV-1 non-nucleoside inhibitors.
Resistance mutations reveal how these mechanisms operate. The HIV-1 M184V substitution reduces susceptibility to lamivudine and emtricitabine by altering interactions near the polymerase active site. K103N can substantially reduce susceptibility to certain older non-nucleoside inhibitors by affecting their binding environment. Other substitutions enhance discrimination against nucleotide analogues or promote removal of an incorporated chain terminator through ATP-dependent excision. Resistance is therefore not a single phenomenon: different mutations can act at substrate selection, inhibitor binding, or post-incorporation steps, and combinations of mutations can interact.
Reverse transcriptase inhibitors suppress susceptible viral replication but do not directly excise an already integrated HIV provirus. In hepatitis B infection, inhibition of reverse transcription likewise does not directly eliminate the nuclear covalently closed circular DNA that serves as a transcriptional template. These persistent forms help explain the distinction between blocking ongoing viral DNA synthesis and removing the underlying viral reservoir. Clinical use of these agents consequently belongs to a broader framework of virological monitoring and combination antiviral therapy rather than to enzyme inhibition considered in isolation.
Laboratory synthesis of cDNA and RNA measurement
In the laboratory, reverse transcriptase converts RNA into cDNA that can be amplified, cloned, or sequenced. Common enzyme platforms derive from Moloney murine leukemia virus and avian myeloblastosis virus, with many commercial reagents incorporating engineered substitutions. These modifications can increase thermal stability, improve processivity, reduce RNase H activity, or alter inhibitor tolerance. Reducing RNase H activity can be useful when the goal is to preserve an RNA template long enough to synthesize a long cDNA molecule.
Primer choice strongly influences which RNAs are represented. Oligo(dT) primers anneal to polyadenylated RNA and are widely used for eukaryotic messenger RNA, but can introduce bias toward transcript ends or prime at internal adenine-rich sequences. Random primers copy a broader RNA population, including abundant ribosomal RNA unless it has been removed. Gene-specific primers restrict the reaction to selected targets and can improve sensitivity or strand discrimination in appropriately designed assays. None of these approaches copies all RNA molecules with identical efficiency.
Reverse transcription polymerase chain reaction combines cDNA synthesis with PCR. In a two-step workflow, reverse transcription and PCR are performed separately, allowing one cDNA preparation to support multiple downstream assays. In a one-step workflow, both reactions occur in the same vessel, reducing handling and opportunities for contamination. The term RT-PCR denotes reverse transcription PCR; quantitative real-time PCR is more precisely abbreviated qPCR, and its RNA-based form RT-qPCR. Reverse transcription is what allows RNA viruses or cellular transcripts to be measured with a DNA amplification method.
The reverse-transcription step is a major source of uncertainty in RNA quantification. RNA degradation, secondary structure, primer binding, inhibitors carried through extraction, and transcript abundance can all affect cDNA yield. Consequently, identical starting amounts of two RNAs do not necessarily produce identical amounts of cDNA. No-reverse-transcriptase controls help detect amplification from contaminating DNA, while no-template controls test for reagent contamination. Reference genes or external RNA standards address different aspects of normalization and assay performance; they do not automatically remove every reverse-transcription bias.
Reverse transcriptase also supports RNA sequencing, including many single-cell and spatial methods. Some protocols exploit an enzyme’s tendency to add a few non-templated nucleotides at the end of a cDNA, enabling a designed template-switching oligonucleotide to append a known sequence. This controlled use of template switching helps capture transcript ends or add amplification handles. However, incomplete copying, internal priming, and unintended switching can still distort transcript representation. Interpreting a cDNA library therefore requires attention to the enzyme and protocol that generated it, not only to the subsequent sequencing technology.
Enzyme engineering and emerging genome technologies
Reverse transcriptase engineering seeks to adapt a naturally variable enzyme family to tasks that differ from viral replication. Desired properties include higher operating temperature, longer continuous synthesis, improved fidelity, broader template compatibility, and resistance to substances that inhibit nucleic-acid enzymes. These properties can conflict: a substitution that improves thermal stability may alter substrate binding, while changes that increase processivity can affect template switching or product release. Enzyme performance is therefore evaluated against the intended assay rather than along a single scale of overall quality.
Temperature is especially important because RNA forms stable secondary structures. Hairpins and more complex folds can stall a polymerase, producing incomplete cDNA and uneven sequence coverage. Thermostable reverse transcriptases can copy at temperatures that destabilize some of these structures. Enzymes derived from group II intron reverse transcriptases have attracted attention because certain members combine thermostability, high processivity, and favorable fidelity characteristics. Their use extends the laboratory repertoire beyond the retroviral enzymes that historically dominated cDNA synthesis. Nevertheless, performance depends on the particular enzyme, buffer, template, and library design.
A distinct application is prime editing, introduced in 2019. This genome-editing approach couples a Cas9 nickase to an engineered reverse transcriptase and uses a prime-editing guide RNA containing both targeting information and a template for the intended DNA change. After a nick is made in the target DNA, the exposed DNA end can pair with a primer-binding segment of the guide RNA. Reverse transcriptase then copies the encoded edit into DNA. Cellular processing of the resulting intermediates determines whether the edited sequence becomes established.
Prime editing illustrates a reversal of the enzyme’s usual laboratory role. Instead of converting an extracted RNA sample into cDNA for analysis, the enzyme writes information supplied by an RNA template into a genomic DNA target. It can support selected substitutions and small insertions or deletions without requiring a conventional donor DNA molecule or a deliberately introduced double-strand break at the target. Its efficiency and by-products vary with target sequence, edit type, guide design, delivery, and cellular repair pathways. The reverse-transcription step is essential, but it is only one part of a multistage editing process.
Retrons are also being developed as intracellular sources of single-stranded DNA for recombination-based engineering and molecular recording. Their reverse transcriptases generate DNA from genetically encoded RNA templates, allowing cells to produce donor sequences rather than receive all donor DNA from an external source. Research also examines reverse transcriptases in bacterial antiviral systems, where genetic context and associated proteins can be crucial to function. For many newly identified enzymes, sequence similarity establishes membership in the reverse transcriptase family more readily than it establishes biological purpose; resolving that purpose requires biochemical assays, genetic experiments, and analysis of the surrounding cellular machinery.